Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 5Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Oligoprogressive 1

Interventions

pembrolizumab 11Nivolumab 6fludarabine phosphate 5fludarabine 5Paclitaxel 5Cyclophosphamide 5Cisplatin 5Cetuximab 5Carboplatin 5atezolizumab 4Specimen Handling 4Pemetrexed 4Docetaxel 4Bevacizumab 4durvalumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3venetoclax 2temsirolimus 2niraparib 2ibrutinib 2enzalutamide 2encorafenib 2binimetinib 2Trastuzumab 2Taxes 2Standard of Care 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Immune Checkpoint Inhibitors × 30 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡